Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics (Nasdaq: KROS) announced four abstracts related to its KER-050 and KER-047 programs will be presented at the virtual 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. Key presentations include:
1. KER-050's role in promoting erythroid differentiation (Publication Number: 2736).
2. KER-050 alleviating cytopenia (Publication Number: 2582).
3. KER-047's effects on serum iron (Publication Number: 769).
4. KER-047 inhibiting ALK2 signaling (Publication Number: 771). These programs target significant hematological disorders with high unmet medical needs.
Keros Therapeutics has initiated a Phase 2 clinical trial for KER-050, targeting anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS). The first two participants have been dosed, with initial data expected by mid-2021. This open-label trial aims to confirm KER-050's safety and tolerability in patients with varying risks of MDS. Results from prior Phase 1 trials showed a robust hematological response in healthy volunteers. KER-050 could potentially address the significant unmet medical needs in MDS, affecting up to 170,000 patients annually in the U.S.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 am ET. Keros specializes in developing novel treatments for hematological and musculoskeletal disorders with high unmet needs. Its lead candidates include KER-050 for cytopenias, KER-047 for anemia and fibrodysplasia ossificans progressiva, and KER-012 for bone loss disorders and pulmonary arterial hypertension.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced positive preclinical results for KER-012 during the ASBMR 2020 Annual Meeting. KER-012, an activin receptor type II ligand trap, significantly increased trabecular bone volume in mice by reducing catabolism and enhancing anabolism. Key findings showed an 82.0% rise in bone volume and significant increases in trabecular thickness and formation rates. KER-012 aims to address conditions like osteoporosis, with potential implications for treating cancer-induced bone loss. CEO Jasbir S. Seehra highlighted the unique mechanism of KER-012 as a significant advancement in bone health treatments.
Keros Therapeutics (KROS) reported its Q2 2020 financial results, highlighting a net loss of $10.8 million, an increase from $2.9 million in Q2 2019. The rise in losses was attributed to heightened research and development efforts, totaling $7.3 million, as well as increased general and administrative expenses amounting to $3.7 million. Keros closed its initial public offering, bringing its cash reserves to $144.7 million, projected to fund operations into 2022. The company plans to initiate multiple Phase 2 trials for its lead programs in 2021.
Keros Therapeutics announced the completion of cohorts in a Phase 1 clinical trial for its lead compound, KER-047, targeting anemias and fibrodysplasia ossificans progressiva. The trial showed target engagement and a reduction in hepcidin, indicating potential for effective iron mobilization. No serious adverse events occurred, with common side effects including headache and nausea. Keros plans to expand the trial further and expects to commence Phase 2 trials in early 2021. The study is conducted in collaboration with Mass General Brigham and NIH’s NCATS.
Keros Therapeutics (KROS), a clinical-stage biopharmaceutical firm, will be included in the Russell 2000® Index effective June 26, 2020. This index represents small-cap U.S. stocks and is utilized widely by institutional investors for benchmarking. Approximately $9 trillion in assets track Russell indexes. Keros specializes in innovative treatments for hematological and musculoskeletal disorders, with notable product candidates including KER-050, KER-047, and KER-012, targeting conditions like anemia and bone loss.
Keros Therapeutics (KROS) presented data from its Phase 1 clinical trial of KER-050 at the 25th Annual Congress of the European Hematology Association. The trial demonstrated that KER-050 was well-tolerated and elicited significant increases in key hematological parameters, including hemoglobin and platelets, in healthy post-menopausal women. Additionally, preclinical studies showed KER-050's potential to enhance hematopoiesis and offered insights into a novel ALK2 kinase inhibitor that could mitigate anemia in iron-refractory iron deficiency anemia (IRIDA) models. Keros plans to initiate Phase 2 trials for KER-050 in patients with myelodysplastic syndromes and myelofibrosis.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced that President and CEO Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 9:00 am ET. Keros is a clinical-stage biopharmaceutical company specializing in treatments for hematological and musculoskeletal disorders with significant unmet needs. Their lead candidates include KER-050 for cytopenias, KER-047 for anemia related to hepcidin, and KER-012 for bone loss disorders.
Keros Therapeutics, Inc. (KROS) reported Q1 2020 financial results and business updates. The company experienced a net loss of $11.9 million, up from $3.2 million in Q1 2019, attributed to R&D and public company transition costs. They completed a Series C financing raising $56 million in March and an IPO generating $110.4 million in April, providing a cash balance of $54.5 million as of March 31, 2020, expected to sustain operations into H2 2022. Progress continues with KER-047 and KER-050, and a Phase 2 trial for KER-050 is set for H2 2020, pending COVID-19 impacts.